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Abstract
Background: Mutations within the tumor suppressor TP53 gene are one of the most common genetic alterations
present at high frequency in human tumors and have been shown to be associated with resistance to radio-
chemotherapy. The lack of the wild type TP53 gene in cancer cells could be exploited for therapeutic advantage
using a sequence of two antagonistic drugs. The aim of this study was to selectively kill p53 deficient cells (FaDu
and H1299) by taxol and to protect p53 wild type cells (A549) by the prior administration of nutlin-3 in comparison
to certain known anticancer drugs (5-fluorouracil, camptothecin, roscovitine).
Methods: Cytotoxic and cytostatic properties of 5-fluorouracil, camptothecin, roscovitine and nutlin-3
administrating alone or in combination with taxol were investigated in vitro by flow cytometry.
Results: It was found that nutlin-3 induced growth arrest and protected A549 cells from taxol. FaDu and H1299
cells responded to the same treatments with mitotic arrest and massive apoptosis. Other compounds
(5-fluorouracil, camptothecin and roscovitine) revealed weaker selectivity and elevated toxicity in comparison
to nutlin-3.
Conclusions: We propose a therapeutic strategy protecting normal cells from taxol while increasing apoptosis
selectively in p53-deficient cells using nutlin-3.
Background
Cancer is a complex family of diseases, characterized by
the deregulation of normal control pathways for cellular
growth. Lung cancer (LC) is the leading cause of death
among human malignancies and is among the most
threatening of them due to its disappointing response to
therapy [1]. Development of LC, which can be separated
roughly into small cell lung cancer (SCLC) or non-small
cell lung cancer (NSCLC), involves multiple genetic
abnormalities. One of the most common changes on
this way is mutation in the tumor suppressor TP53 gene
with a mutations frequency of 50% and 70% in NSCLC
and SCLC, respectively [2-4]. Such genetic abnormality
is shown to be associated with a poorer survival prog-
nosis and increased cellular resistance to therapy [5-7].
Thus, there is an urgent need for development of target-
driven novel class of anti-cancer drug against this deadly
disease.
The discovery of new cancer-related therapeutic tar-
gets is mainly based on the identification of genes
involved in pathways selectively exploited in cancer cells
[8,9]. For example, the lack of wt p53 (the product of
TP53 gene) in cancer cells can be utilized for therapeu-
tic advantage by selective killing of p53 deficient (p53-/-)
cancer cells and by protecting p53 wild type cells
(p53wt) at normal proliferation rates using antagonistic
drugs [10,11]. It was demonstrated that certain antican-
cer drugs could selectively arrest p53wt cells in G1 or G2
phases of the cell cycle by activation of the p53 pathway
and thereby protects them from antimitotic agent. E.g.
taxol, which simultaneously kills and/or blocks p53-/-
cancer cells during mitosis [12,13].
However, genotoxic drugs can trigger multiple mole-
cular events including activation of p53-independent
checkpoints and thus may partially protect the cancer
cells during chemotherapy [3]. This can be avoided by
using agents targeted specifically at the p53 pathway. In
proliferating cells that are not subjected to stress, p53
level is tightly controlled by its negative regulator
MDM2, which binds p53 and modulates its
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transcriptional activity and stability [3,14-16]. MDM2 is
an E3 ubiquitin ligase that binds the tumor suppressor
and facilitates its ubiquitin-dependent degradation [17].
The MDM2 binding domain overlaps with the transcrip-
tional activation domain of p53, and therefore MDM2
binding also inhibits the transcriptional activity of p53,
thus effectively impairing its function [18]. Disruption of
the p53-MDM2 interaction, therefore, provides an
attractive strategy for activating p53. It was shown that
nutlin-3 could selectively disrupt the interaction
between p53 and MDM2 [19] inducing cell cycle arrest
in normal murine and human cells [3,14-16,20] cells
without initiation of apoptosis. This presents unique
opportunities for p53-dependent modulation of the cell
cycle of the proliferating p53wt cells of the intact sur-
rounding tissues to protect them from the taxol during
chemotherapy of p53-/- tumors [21].
In this context, the goal of our work was to evaluate
the effectiveness of the MDM2 antagonist nutlin-3 in
comparison to certain anticancer drugs (5-fluorouracil,
camptothecin, roscovitine) with known cytostatic effects
to protect proliferating p53wt cells from taxol in the
combined cell cycle associated therapy leading to selec-
tive killing of p53-/- cells.
Methods
Cell culture
Established human cell lines of different tumor entities,
i.e. near triploid (~3C) NSCLC cell line A549 presenting
wild type TP53 gene, near hexaploid (~6C) NSCLC cell
line H1299 with TP53-null gene and near triploid (~3C)
pharyngeal squamous-cell carcinoma (PSCC) cell line
FaDu presenting mutated TP53 gene from DSMZ (Ger-
many) were used in this study. Cells were cultured in
Dulbecco Modified Eagle Medium routinely supple-
menting with 10% heat-inactivated fetal calf serum
(Gibco, France) and incubated at 37°C in humidified 5%
CO2 atmosphere with media replacement every 2 days.
When the cell cultures reached 90% confluence they
were harvested using 0.25% trypsin and 1 mM EDTA
solution (Sigma, Germany) and reseeded in new flasks
at a density of 10-15 × 103cells/cm2. Cell counts in the
samples were determined with a coulter counter (CASY,
Model TTC, Schärfe System, Germany).
Flow cytometry
To have a possibility for comparison of our results with
previousfindings [3,12,14-16,19,20,22-28] and taking into
account that in solid tumor-derived cell lines p53-depen-
dent apoptosis is usually delayed for 24 h [19] the cells
were placed in culture medium (2 × 105cells/mL) 1 day
before exposure to 5-fluorouracil (1, 3, 10 and 30 μM),
camptothecin (10, 30, 100 and 300 nM), nutlin-3 (1, 3, 10
and 30 μM), roscovitine (1, 3, 10 and 30 μM) and taxol
(1, 3, 10, 30 and 100 nM). All compounds were pursued
from Sigma (Germany). To test an advantage of the
nutlin-3 in the selective protect p53wt A549 cells from
taxol, all cell cultures according to [3,29] were incubated
for a 24 hours period in parallel with 5-fluorouracil
(3 μM), camptothecin (10 nM), roscovitine (10 μM) and
nutlin-3 (3 μM) respectively. Then, taxol (10 nM) was
added and cell cultures were incubated for another 24
hours period. Because the stock solutions (×1000) of the
test compounds were prepared in dimethylsulfoxid
(DMSO, Sigma, Germany), all cultures including the con-
trol samples were made 0.1% in DMSO. After 24 hours of
appropriate treatment cells were removed from the cul-
ture and prepared for analysis by flow cytometry as pre-
viously described [30]. Cells were briefly washed with
phosphate-buffered saline (PBS) and centrifuged at 100 g
for 10 min. The cell pellet was re-suspended in 100 μl of
PBS, fixed in 70% (vol/vol) ethanol by adding 1 ml of
cold (-20°C) ethanol and stored overnight at -20°C. The
cells were spun down again and the pellet was suspended
in 1.5 ml of PBS at room temperature. After centrifuga-
tion the cell pellet was suspended in 1 ml DNA staining
solution containing 50 μg PI and 0.2 mg RNase (both
Sigma, Germany) and incubated for at least 45 min at
room temperature in the dark. About 2 × 105 cells per
sample were analyzed by flow cytometry (CyFlow, Partec,
Germany). The excitation wavelength was 488 nm, and
red fluorescence (>590 nm for PI) was recorded. In addi-
tion, the parameters for forward scatter (FSC) and side
scatter (SSC) were determined. For each variable (expo-
sure condition, culture period etc.) a minimum of 6 sam-
ples were quantified. The flow cytometer was calibrated
with 2.5 μm polyfluorescent beads (AlignFlow, Molecular
Probes, Eugene, OR) before each series of measurements.
The fractions of apoptotic cells with sub-G1 DNA
content as well as the fractions of cells in G0 + 1, S and
G2 + M phases of the cell cycle were quantified accord-
ing to the level of measured fluorescence, FSC and SSC
using a CyFlow software (Partec, Germany).
Statistics
The experimental results are expressed as the mean ±
standard deviation (mean ± s.d.) of 6 independent
experiments. Analysis of variance (ANOVA) was
performed.
Results
In vitro cultures of exponentially growing A549, H1299
and FaDu intact cell cultures had different cell cycle dis-
tributions with 62 ± 1%, 46 ± 1% and 59 ± 1% in G0 + 1,
26 ± 1%, 36 ± 1% and 26 ± 1% in S and 12 ± 1%, 18 ±
1% and 15 ± 1% in G2 + M phases respectively. In the
first part of investigation all cell cultures were incubated
for a 24 hours period in parallel with dissimilar
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concentrations of 5-fluorouracil, camptothecin, nutlin-3,
roscovitine and taxol with respect to the toxicity and
cell cycle effects of test compounds.
No perturbations of the cell cycle were registered in
the control cell cultures. With increasing concentrations
of the tested compounds the cell cycle progression was
affected in varying degrees (Table 1).
5-fluorouracil provoked a dose dependent delay in S
phase (3-30 μM, p < 0.05) in all three cell lines indepen-
dent of their p53 status. It was accompanied by decreas-
ing percentage of G0 + 1 cells in A549 (10-30 μM,
p < 0.05), FaDu (10 μM, p < 0.05) and H1299 (3-30 μM,
p < 0.05).
Camptothecin was the most toxic of the test com-
pounds used showing a dose dependent increase of
apoptotic cell proportion (p < 0.05), causing cell cycle
arrest at S phase (p < 0.05) and reduction of G0 + 1 cells
proportion (p < 0.05) at concentrations of 30-300 nM in
all three cell lines independent of their p53 status.
Nutlin-3 at concentrations of 3-30 M caused reduc-
tion of S cells proportion (p < 0.05) with increase of
percentage in G0 + 1 (p < 0.05) and G2 + M phases (p <
0.05) in p53wt A549 cells. No remarkable changes in the
cell cycle distribution were registered in p53-/- FaDu
and H1299 cells. These observations were accompanied
by an increasing proportion of apoptotic cells (30 μM,
p < 0.05) in all cell lines used.
Roscovitine caused increase of A549 (3-30 μM, p <
0.05), FaDu (3-30 μM, p < 0.05) and H1299 (10-30 μM,
p < 0.05) cells proportion at G2 + M phase. Decreases
of G0 + 1 cells percentage were registered in A549
(30 μM, p < 0.05), FaDu (10-30 μM, p < 0.05) and
Table 1 Effects of test substances on proliferation of certain cancer cells.
The distribution of cells in different cell cycle phases (%)1
A549 FaDu H1299
<2C2 G0 + 1 S G2 + M <2C G0 + 1 S G2 + M <2C G0 + 1 S G2 + M
5-fluorouracil (μM)
1 2 ± 1 62 ± 2 27 ± 1 11 ± 1 2 ± 1 51 ± 3 31 ± 2 16 ± 1 2 ± 1 56 ± 2 31 ± 2 15 ± 1
3 2 ± 1 57 ± 2 33 ± 1 10 ± 1 2 ± 1 55 ± 3 26 ± 2 19 ± 1 2 ± 1 52 ± 2 34 ± 2 14 ± 1
10 2 ± 1 31 ± 2 61 ± 2 8 ± 2 2 ± 1 28 ± 1 52 ± 1 20 ± 1 2 ± 1 52 ± 2 32 ± 2 16 ± 2
30 3 ± 1 46 ± 2 47 ± 2 7 ± 2 3 ± 1 48 ± 2 44 ± 1 18 ± 1 5 ± 1 50 ± 2 33 ± 2 17 ± 2
Camptothecin (nM)
10 2 ± 1 42 ± 4 24 ± 2 28 ± 3 6 ± 2 18 ± 1 24 ± 2 58 ± 3 2 ± 1 17 ± 4 40 ± 9 43 ± 9
30 8 ± 2 16 ± 2 68 ± 4 16 ± 4 10 ± 3 6 ± 1 77 ± 3 17 ± 3 12 ± 2 11 ± 3 69 ± 3 19 ± 2
100 32 ± 4 14 ± 2 69 ± 4 17 ± 2 17 ± 2 21 ± 3 68 ± 4 11 ± 1 17 ± 3 22 ± 1 56 ± 4 22 ± 3
300 45 ± 6 45 ± 4 45 ± 4 10 ± 2 15 ± 3 40 ± 3 50 ± 3 10 ± 2 15 ± 2 35 ± 3 40 ± 4 25 ± 2
Nutlin-3 (μM)
1 2 ± 1 61 ± 2 28 ± 2 11 ± 1 2 ± 1 40 ± 4 38 ± 3 22 ± 3 2 ± 2 57 ± 1 29 ± 2 14 ± 1
3 2 ± 1 71 ± 2 13 ± 1 16 ± 1 2 ± 1 44 ± 2 34 ± 2 22 ± 2 2 ± 1 57 ± 3 25 ± 2 18 ± 2
10 2 ± 1 69 ± 1 7 ± 3 24 ± 3 4 ± 1 45 ± 3 34 ± 2 21 ± 2 4 ± 1 54 ± 4 27 ± 4 19 ± 2
30 5 ± 1 68 ± 2 6 ± 1 26 ± 2 8 ± 1 48 ± 3 32 ± 2 20 ± 2 7 ± 1 63 ± 2 19 ± 2 18 ± 1
Roscovitine (μM)
1 2 ± 1 60 ± 2 24 ± 2 16 ± 1 2 ± 1 41 ± 4 39 ± 4 20 ± 2 2 ± 1 47 ± 1 36 ± 3 17 ± 2
3 2 ± 1 59 ± 4 20 ± 3 21 ± 1 2 ± 1 43 ± 1 32 ± 1 25 ± 1 2 ± 1 52 ± 1 33 ± 1 15 ± 2
10 5 ± 1 59 ± 4 20 ± 3 21 ± 1 4 ± 1 38 ± 2 27 ± 2 35 ± 2 4 ± 2 49 ± 2 29 ± 1 22 ± 1
30 10 ± 4 51 ± 5 24 ± 3 24 ± 3 10 ± 3 34 ± 3 30 ± 2 36 ± 2 11 ± 4 43 ± 3 26 ± 2 31 ± 3
Taxol (nM)
1 9 ± 2 60 ± 4 25 ± 4 15 ± 2 21 ± 2 39 ± 3 34 ± 6 27 ± 4 13 ± 6 48 ± 6 30 ± 3 22 ± 5
3 36 ± 5 41 ± 3 32 ± 5 27 ± 2 30 ± 5 22 ± 4 35 ± 5 43 ± 7 35 ± 6 40 ± 1 40 ± 1 20 ± 1
10 35 ± 6 22 ± 4 29 ± 3 51 ± 6 33 ± 6 12 ± 2 19 ± 4 69 ± 4 42 ± 5 34 ± 4 34 ± 4 32 ± 7
30 16 ± 4 15 ± 2 17 ± 3 68 ± 5 16 ± 3 4 ± 1 11 ± 2 85 ± 2 44 ± 4 18 ± 1 36 ± 4 46 ± 7
100 10 ± 2 18 ± 4 18 ± 3 64 ± 5 8 ± 2 5 ± 1 9 ± 3 87 ± 3 30 ± 4 21 ± 3 23 ± 3 55 ± 2
Control
- 3 2 ± 1 62 ± 1 26 ± 1 12 ± 1 2 ± 1 46 ± 2 36 ± 1 18 ± 1 2 ± 1 59 ± 2 26 ± 2 15 ± 1
The data show the effects of the test substances on the cell cycle of A549, FaDu and H1299 cells after exposure for 1 day (average ± SD of 6 independent
experiments). Significant differences (p < 0.05) to control cultures are indicated in bold print.
1The distribution of cells in different cell cycle phases was calculated from the population of cycling cells (G0 + 1 + S + G2 + M = 100%).
2The percentage of hypodiploid cells (<2C DNA content) was calculated from the total number of cells.
3Since the test compounds were dissolved in a DMSO stock solution, control cells cultures were made in 14 mM (0.1%) DMSO.
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H1299 (1-30 μM, p < 0.05) cells. These changes were
accompanied by the increasing proportion of apoptotic
cells (30 μM, p < 0.05) in all three cell lines.
Taxol caused dose dependent accumulation of cells
arresting at the G2 + M phase accompanied by the
reduction of the proportion of the cells in G0 + 1 and S
phases (3-100 μM, p < 0.05) independent of their p53
status. At lower concentrations (1-30 nM, p < 0.05), a
large fraction of cells was released from the block in 24
hours and became apoptotic. At higher concentrations
(30-100 nM) the proportion of apoptotic cell was
reduced due to elongation of G2 + M block.
To test the ability of the analyzed compounds to
selectively protect p53wt A549 cells and to selectively
kill p53-/- H1299 and FaDu cells by taxol, all cell cul-
tures were incubated for a 24 hours period in parallel
with DMSO (0.1%, control), 5-fluorouracil (3 μM),
camptothecin (10 nM), roscovitine (10 μM), nutlin-3
(3 μM) and taxol (Tax, 10 nM) respectively (Figure 1).
Then, taxol (10 nM) was added and cell cultures were
incubated for another 24 hours period. It was found
(Figure 2) that the administration of taxol alone
increased the proportion of apoptotic cells in A549 (35
± 6%, p < 0.001), FaDu (33 ± 4%, p < 0.001) and H1299
(42 ± 5%, p < 0.001) cell lines. Pretreatment with nutlin-
3 protected p53wt A549 cells (but not p53-/- FaDu and
H1299 cells) from taxol, dramatically reduced the pro-
portion of apoptotic cells (2 ± 1%, p < 0.001; 29 ± 2%, p
< 0.001; 52 ± 4%, p > 0.05, correspondently) and
revealed the similar distribution through the cell cycle,
as it was registered after the administration of nutlin-3
alone.
Pretreatment with roscovitine also protected some of
A549. However, roscovitine increased proportion of
apoptotic A549 cells as well as protected some of p53-/-
FaDu cells due to a block in G2 + M phase. As a result
proportion of apoptotic A549, FaDu and H1299 cells
reduced to 20 ± 2%, p < 0.001; 21 ± 2%, p < 0.001; 49 ±
3%, p > 0.05, correspondently. The other compounds
analyzed (5-fluorouracil, camptothecin) revealed low
selectivity and demonstrated high toxicity as well.
Discussion
Our findings in cell cycle specific interaction of antican-
cer drugs (5-fluorouracil, camptothecin, nutlin-3, ros-
covitine, taxol) generally validate previous reports in the
literature. So, it is confirmed that treatment of cells with
5-fluorouracil widely using in the treatment of a range
of cancers leads to an accumulation of cells in S-phase
and induces p53 apoptosis [22]. Naturally occurring
cytotoxic alkaloid camptothecin reveals the highest toxi-
city from the test compounds due to the possibility irre-
versibly binding to the DNA-topoisomerase I complex
independent of 53 status of cells [23]. Roscovitine inhi-
biting cyclin-dependent kinases via direct competition in
the ATP-binding site [26] provokes G2-M arrest and at
the highest using doses induces apoptosis in all of used
cells. Following binding to B-tubulin microtubule-tar-
geted agent taxol causes mitotic arrest and apoptosis in
variety of cancer cells [27]. Such blocked cells could be
Figure 1 The effect of certain compounds on cell cycle distribution. Cell cycle distribution in 24 hours after administration of DMSO (0.1%,
control), 5-fluorouracil (5FU, 3 μM), camptothecin (Cam, 10 nM), roscovitine (Ros, 10 μM), nutlin-3 (Nut, 3 μM) and taxol (Tax, 10 nM).
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arrested during next several days of culture. In contrast,
at lower concentrations a large fraction of cells could
release from the block in 24 hours and became apoptotic
[28]. Our study in agreement with previous findings [31]
showed that nutlin-3 in low concentrations (1-10 μM)
induced depletion of the S-phase fraction, causing arrest
at G1/S and/or G2/M phases in p53
wt A549 cells without
apparent apoptosis. Last may be explained by the known
fact that the induction of apoptotic genes alone some-
times is not sufficient to provoke apoptosis, as the high
levels of cell cycle inhibitor, such as p21 dominantly lead
to the cell cycle arrest [24]. This was supported using
MI-43 (another compound that disrupted Mdm2-p53
binding) which at low concentrations induced remark-
able induction of p53 leading to 90% cells arrested of
A549 cells at the G1 phase without apparent apoptosis,
although Puma and Noxa were also induced. However, at
higher drug concentration cells underwent apoptosis
even with a moderate further increase of Puma and
Noxa abbrgrp>25].
Previous studies show that elevated concentrations of
nutlin-3 induced p53- and p21-dependent cell cycle
arrest and p53-dependent cell death in different p53wt
tumor cell lines including A549 [15,16,18,19,21,25,
27,29,31]. The p53 activation by nutlin-3 has been
shown to lead cell cycle arrests in normal human [3,15]
fibroblasts, endothelial [16] and epithelial [20] cells
without initiation of apoptosis. Therefore, NSCLC cell
line A549 seems to be more sensitive to the induction
of apoptosis through the activation of p53 pathway and
our results might be translated to the control cell lines
mentioned above.
Taxol and other mitotic chemotherapeutics are fre-
quently used together with genotoxic drugs activating
the p53 pathway in wild-type p53 cells via genotoxic
stress [10]. However, the usefulness of DNA damaging
agent is limited by their ability to activate p53-indepen-
dent checkpoint mechanism in cancer cells with mutant
p53 [11]. The nutlin-3 works solely through stabilization
and activation of p53 gene. Therefore, protection by
nutlin-3 is strictly dependent on the p53 status of the
cells [21]. Using MDM2 antagonist nutlin-3 as selective
activator of p53 pathway, we have shown that induction
of cell cycle arrest can protect p53wt NSCLC (A549)
cells from the cytotoxicity of taxol selectively killing of
p53-/- PSCC cells (FaDu) and p53-/- NSCLC (H1299)
cells. Our results confirmed previously reported syner-
gistic interaction of the nutlin-3/taxol treatment of the
p53-/- cancer cells and protection of normal proliferating
fibroblasts or p53wt colon cancer cells [3].
Although the experiments described in this report use
taxol as a mitotic inhibitor, nutlin-3 halted cell cycle
progression at the G1/S and G2/M phases and can thus
attenuate the activity of S-phase- and M-phase-specific
drugs. For example, treatment of normal proliferating
fibroblasts or keratinocytes with nutlin-3 protects these
cells against gemcitabine and Ara-C killing proliferating
p53-/- cancer cells in S-phase [29].
Figure 2 Cell cycle distribution in 24 hours after combined treatment. Cell cycle distribution in 24 hours after administration of DMSO
(0.1%, Control), 5-fluorouracil (5FU, 3 μM), camptothecin (Cam, 10 nM), roscovitine (Ros, 10 μM), nutlin-3 (Nut, 3 μM), followed by administration
of taxol (Tax, 10 nM) for another 24 hours.
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From other side, previous findings have suggested that
nutlin-3 at higher concentrations might also offer a new
therapeutic option to patients with tumors that express
wild-type p53 either as single agent (Vassilev, 2005;
Tovar et al., 2005) or as combination therapy (Kojima et
al., 2005; Stuhmer et al., 2005). Nutlins have been
shown to enter multiple types of cultured cells and inhi-
bit the p53-MDM2 interaction in the cellular context
with a high degree of specificity, resulting in the p53
stabilization, p21 induction, cell cycle arrest in G1 and
G2 phases, apoptosis and growth inhibition of proliferat-
ing cancer cells [19]. It is interesting that treatment of
nude mice with nutlin-3 has been shown might effec-
tively inhibit the growth of tumor xenografts without
revealing of overt toxicity, thus suggesting that normal
tissues may have higher tolerance to p53 activation [21].
Our findings open possibility to establish a genetically
determined strategy in the lung cancer treatment.
Depending of genetic status of tumor nutlin-3 might be
administrated as an agent for activation of the p53 path-
way resulting in p53 stabilization, p21 induction, cell
cycle arrest in G1 and G2 phases, apoptosis and growth
inhibition of cancer cells or in combination with taxol
as a compound protecting surrounding normal tissue.
However, an inter-organ metabolism of nutlin-3 might
be critical to its absorption, distribution and modifica-
tion of the resulting therapeutic effects in vivo.
Therefore, additional in vivo experiments in which the
therapeutic role of nutlin-3 is assessed on multiple nor-
mal tissues in human tumor xenografts with different
p53 status may help to better understand the clinical
potential of this approach.
Conclusions
The therapeutic strategy protecting normal cells from
taxol, while selectively increasing apoptosis in p53-defi-
cient cells is proposed. Nutlin-3 application opens possibi-
lity to establish a genetically determined strategy in the
lung cancer treatment. However, metabolism of used com-
pounds in different tissues should be taken into account
for evaluation of therapeutic effects of this approach.
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